PROTEIN POLYMER TECHNOLOGIES SIGNS AGREEMENT FOR SURGICAL
SEALANT PRODUCT
SAN DIEGO, (CA) -- July 2, 2007 --
Protein Polymer Technologies, Inc. (OTC BB:PPTI.OB -
News), a biotechnology device company that is a pioneer
in protein design and synthesis, announced today that
they have entered into an agreement with a multinational
pharmaceutical and medical device company. According
to the agreement, PPTI will provide genetically engineered
protein polymer biomaterials for use as surgical sealants. "Our
sealant products have consistently performed well in
evaluations by our corporate partners. We are excited
about their demonstrated potential and look forward to
further product development," said William N. Plamondon,
CEO of Protein Polymer Technologies, Inc.
Wound closure after surgery or trauma using conventional sutures
and staples sometimes results in post-operative complications
such as persistent internal bleeding, fluid leaks after
gastrointestinal surgery, or air leaks after lung surgery.
In 2005, it was estimated that 70 million surgical
procedures
worldwide would benefit from the use of surgical sealants,
glues and other wound closure products used in conjunction
with sutures and staples. PPTI believes its protein
polymer sealants and adhesives can improve the outcome
of surgical
wound closure by substantially reducing fluid and air
leaks, especially as applied to endoscopic procedures
in which
access to the traumatized tissue is limited.
PPTI is also in discussions with several U.S. and international
biotechnology and medical device companies, which
are evaluating PPTI's adhesion barrier and drug delivery
product applications.
These products are intended to improve surgical outcomes
by reducing adhesion formation and delivering to
the
surgical site beneficial pharmacological agents.
Investor/Media Contact:
Erin Davis
Director of Communications and Investor Relations
Protein Polymer Technologies, Inc.
(858) 558-6064 x 120
Email Contact |
|
About
Protein Polmer Technologies
Protein Polymer Technologies, Inc. is a biotechnology company that discovers
and develops innovative therapeutic devices to improve medical and surgical
outcomes. The Company focuses on developing technology and products to be used
for soft tissue augmentation, tissue adhesives and sealants, wound healing
support and drug delivery devices. Protein Polymer Technologies' proprietary
protein-based biomaterials are uniquely tailored to optimize clinical performance
and contain no human or animal components that could potentially transmit or
cause disease. The company is headquartered in San Diego, California. For additional
information about the company, please visit http://www.ppti.com.
To date, PPTI has been issued twenty-six U.S. Patents on its core technology
with corresponding issued and pending patents in key international markets.
Safe Harbor
This press release contains forward-looking statements
that are based on management's views and expectations.
Actual results could differ materially from those expressed
here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with
the Company's activities include raising adequate capital
to continue operations, scientific and product development
uncertainties, competitive products and approaches, continuing
collaborative partnership interest and funding, regulatory
testing and approvals, and manufacturing scale up. The
reader is encouraged to refer to the Company's 2006 Annual
Report Form 10-KSB, and recent
filings with the Securities and Exchange Commission,
copies of which are available from the Company, to further
ascertain the risks associated with the above statements.
